A Study to Evaluate Safety and Tolerability of IV or SC D... | NCT01031836

NCT01031836

Status Module

Sponsor/Collaborators Module

Name	Class
MedImmune LLC	INDUSTRY

Oversight Module

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
MEDI-545 1.0 mg/kg	Experimental	Cohort 1	Drug: MEDI-545
MEDI-545 3.0 mg/kg	Experimental	Cohort 2	Drug: MEDI-545
MEDI-545 10.0 mg/kg	Experimental	Cohort 3	Drug: MEDI-545
MEDI-545 100 mg	Experimental	Cohort 4	Drug: MEDI-545
MEDI-545 600 mg	Experimental	Cohort 5	Drug: MEDI-545 600
MEDI-545 1,200 mg	Experimental	Cohort 6	Drug: MEDI-545

Interventions

Name	Type	Description	Arm Group Labels	Other Names
MEDI-545	Drug	Stage I: MEDI-545 1.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses. Stage II: MEDI-545 1.0 mg/kg IV once every 2 weeks for a total of 79 doses.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of Participants With Each Category of Adverse Events in Stage I		Stage I (up to 1 year)
Number of Participants in Each Category of Adverse Events (AE) in Stage II		Stage II (1 year to 3.5 years after first dose)

Secondary Outcomes

Measure	Description	Time Frame
Area Undre Curve (AUC) of MEDI-545 After First Dose in Stage I		After first dose in Stage I (0 upto 28 days)
AUC0-14 of MEDI-545 After First Dose in Stage I	Summary of area under the concentration-time curve from zero to Day 14.

Eligibility Module

Contacts/Locations Module

Overall Officials

Name	Affiliation	Role
Tsutomu Takeuchi	Department of Internal Medicine School of Medicine Keio University	Principal Investigator
Yoshiya Tanaka	The University Hospital, University of Occupational and Environmental Health, Japan	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
Research Site		Chiba		260-8712	Japan
Research Site

References Module

No data available

No data is available for this block.

IPD Sharing Statement Module

No data available

No data is available for this block.

Results Section

Participant Flow Module

ID	Title	Description
FG000	MEDI-545 1.0 mg/kg IV	MEDI-545 1.0 mg/kg IV once every 2 weeks
FG001	MEDI-545 3.0 mg/kg IV	MEDI-545 3.0 mg/kg IV once every 2 weeks

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

Intervention Browse Module

Masking Info

Type of Units Analyzed

Arm/Group Information

ID	Title	Description
BG000	MEDI-545 1.0 mg/kg IV	MEDI-545 1.0 mg/kg IV once every 2 weeks
BG001	MEDI-545 3.0 mg/kg IV	MEDI-545 3.0 mg/kg IV once every 2 weeks
BG002	MEDI-545 10.0 mg/kg IV	MEDI-545 10.0 mg/kg IV once every 2 weeks
BG003	MEDI-545 100 mg SC	MEDI-545 100 mg SC once every 2 weeks
BG004	MEDI-545 600 mg IV	MEDI-545 600 mg IV once every 4 weeks
BG005	MEDI-545 1200 mg IV	MEDI-545 1200 mg IV once every 4 weeks
BG006	Total	Total of all reporting groups

Units	Counts
Participants	BG0005 BG0015 BG0025 BG0035 BG0045 BG0055 BG00630

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Mean

Standard Deviation

years

Title

Denominators

Categories

Title	Measurements
	OG000261.98± 16.8(226.18 to 332.80) OG001647.93± 7.4(614.06 to 681.80) OG0023040.83± 24.2(2284.94 to 3670.57)

Secondary

AUC0-14 of MEDI-545 After First Dose in Stage I

Summary of area under the concentration-time curve from zero to Day 14.

PK populaton

Posted

Geometric Mean

Geometric Coefficient of Variation

day*ug/mL

After first dose in Stage I

ID	Title	Description
OG000	MEDI-545 1.0 mg/kg IV	MEDI-545 1.0 mg/kg IV once every 2 weeks
OG001	MEID-545 3.0 mg/kg IV	MEID-545 3.0 mg/kg IV once every 2 weeks
OG002	MEDI-545 10.0 mg/kg IV	MEDI-545 10.0 mg/kg IV once every 2 weeks
OG003	MEDI-545 100mg SC	MEDI-545 100mg SC once every 2 weeks
OG004	MEDI-545 600mg IV	MEDI-545 600mg IV once every 4 weeks

Primary

Number of Participants With Each Category of Adverse Events in Stage I

Safety population

Posted

Count of Participants

Participants

Stage I (up to 1 year)

ID	Title	Description
OG000	MEDI-545 1.0 mg/kg IV	MEDI-545 1.0 mg/kg IV once every 2 weeks
OG001	MEID-545 3.0 mg/kg IV	MEID-545 3.0 mg/kg IV once every 2 weeks
OG002	MEDI-545 10.0 mg/kg IV	MEDI-545 10.0 mg/kg IV once every 2 weeks
OG003	MEDI-545 100mg SC	MEDI-545 100mg SC once every 2 weeks
OG004	MEDI-545 600mg IV	MEDI-545 600mg IV once every 4 weeks
OG005	MEDI-545 1200mg IV

Secondary

Maximum Observed Concentration (Cmax) of MEDI-545 After First Dose in Stage I

PK populaton

Posted

Geometric Mean

Geometric Coefficient of Variation

ug/mL

After first dose in Stage I

ID	Title	Description
OG000	MEDI-545 1.0 mg/kg IV	MEDI-545 1.0 mg/kg IV once every 2 weeks
OG001	MEID-545 3.0 mg/kg IV	MEID-545 3.0 mg/kg IV once every 2 weeks
OG002	MEDI-545 10.0 mg/kg IV	MEDI-545 10.0 mg/kg IV once every 2 weeks
OG003	MEDI-545 100mg SC	MEDI-545 100mg SC once every 2 weeks
OG004	MEDI-545 600mg IV	MEDI-545 600mg IV once every 4 weeks
OG005	MEDI-545 1200mg IV

Secondary

Change From Baseline in 21-gene Signature Fold Change in Stage I

21-gene signature fold change is pharmacodynamics (PD) parameter measuring expression of type I IFN-inducible gene.

Safety population

Posted

Mean

Standard Deviation

fold change

Stage I

ID	Title	Description
OG000	MEDI-545 1.0 mg/kg IV	MEDI-545 1.0 mg/kg IV once every 2 weeks
OG001	MEID-545 3.0 mg/kg IV	MEID-545 3.0 mg/kg IV once every 2 weeks
OG002	MEDI-545 10.0 mg/kg IV	MEDI-545 10.0 mg/kg IV once every 2 weeks
OG003	MEDI-545 100mg SC	MEDI-545 100mg SC once every 2 weeks
OG004	MEDI-545 600mg IV	MEDI-545 600mg IV once every 4 weeks

Secondary

Number of Participants With Positive Anti-drug Antibody (ADA) During Stage I

Safety population

Posted

Count of Participants

Participants

Stage I

ID	Title	Description
OG000	MEDI-545 1.0 mg/kg IV	MEDI-545 1.0 mg/kg IV once every 2 weeks
OG001	MEID-545 3.0 mg/kg IV	MEID-545 3.0 mg/kg IV once every 2 weeks
OG002	MEDI-545 10.0 mg/kg IV	MEDI-545 10.0 mg/kg IV once every 2 weeks
OG003	MEDI-545 100mg SC	MEDI-545 100mg SC once every 2 weeks
OG004	MEDI-545 600mg IV	MEDI-545 600mg IV once every 4 weeks
OG005	MEDI-545 1200mg IV

Primary

Number of Participants in Each Category of Adverse Events (AE) in Stage II

Safety population

Posted

Count of Participants

Participants

Stage II (1 year to 3.5 years after first dose)

ID	Title	Description
OG000	MEDI-545 1.0 mg/kg IV	MEDI-545 1.0 mg/kg IV once every 2 weeks
OG001	MEID-545 3.0 mg/kg IV	MEID-545 3.0 mg/kg IV once every 2 weeks
OG002	MEDI-545 10.0 mg/kg IV	MEDI-545 10.0 mg/kg IV once every 2 weeks
OG003	MEDI-545 100mg SC	MEDI-545 100mg SC once every 2 weeks
OG004	MEDI-545 600mg IV	MEDI-545 600mg IV once every 4 weeks
OG005	MEDI-545 1200mg IV

Arm/Groups

ID	Title	Description	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	MEDI-545 1.0 mg/kg IV	MEDI-545 1.0 mg/kg IV once every 2 weeks	5	0	5	5	5
EG001	MEDI-545 3.0 mg/kg IV	MEDI-545 3.0 mg/kg IV once every 2 weeks	5	3	5	4	5
EG002	MEDI-545 10.0 mg/kg IV	MEDI-545 10.0 mg/kg IV once every 2 weeks	5	3	5	5	5
EG003	MEDI-545 100 mg SC	MEDI-545 100 mg SC once every 2 weeks	5	4	5	5	5
EG004	MEDI-545 600 mg IV	MEDI-545 600 mg IV once every 4 weeks	5	2	5	5	5
EG005	MEDI-545 1200 mg IV	MEDI-545 1200 mg IV once every 4 weeks	5	5	5	5	5

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Notes	Statistical Information
Systemic lupus erythematosus	Musculoskeletal and connective tissue disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0000 events0 affected5 at risk EG0012 events2 affected5 at risk EG0021 events1 affected5 at risk EG0030 events0 affected5 at risk
Cataract	Eye disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0000 affected5 at risk EG0010 affected5 at risk EG0021 affected5 at risk EG003
Osteonecrosis	Musculoskeletal and connective tissue disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0000 affected5 at risk EG0010 affected5 at risk EG0020 affected5 at risk EG003
Pancytopenia	Blood and lymphatic system disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0000 affected5 at risk EG0010 affected5 at risk EG0021 affected5 at risk EG003
Auditory disorders	Ear and labyrinth disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0000 affected5 at risk EG0010 affected5 at risk EG0020 affected5 at risk EG003
Cervix carcinoma stage 0	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0000 affected5 at risk EG0011 affected5 at risk EG0020 affected5 at risk EG003
Systemic lupus erythematosus	Musculoskeletal and connective tissue disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Osteoarthritis	Musculoskeletal and connective tissue disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Intervertebral disc protrusion	Musculoskeletal and connective tissue disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Bronchitis	Infections and infestations	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Pneumonia	Infections and infestations	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Pneumonia pneumococcal	Infections and infestations	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Pyelonephritis	Infections and infestations	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Sepsis	Infections and infestations	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Acute myocardial infarction	Cardiac disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Prinzmetal angina	Cardiac disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Cardiac ventricular thrombosis	Cardiac disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Cataract	Eye disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0021 affected4 at risk EG003
Splenic infarction	Blood and lymphatic system disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Dental caries	Gastrointestinal disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Budd-Chiari syndrome	Hepatobiliary disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Cerebral infaraction	Nervous system disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0021 affected4 at risk EG003
Abortion missed	Pregnancy, puerperium and perinatal conditions	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Hip arthroplasty	Surgical and medical procedures	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Deep vein thrombosis	Vascular disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Notes	Statistical Information
Nasopharyngitis	Infections and infestations	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0002 affected5 at risk EG0014 affected5 at risk EG0023 affected5 at risk EG0033 affected5 at risk EG004
Upper respiratory tract infection	Infections and infestations	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0000 affected5 at risk EG0011 affected5 at risk EG0021 affected5 at risk EG003
Otitis media	Infections and infestations	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0001 affected5 at risk EG0011 affected5 at risk EG0020 affected5 at risk EG003
Diarrhoea	Gastrointestinal disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0003 affected5 at risk EG0012 affected5 at risk EG0021 affected5 at risk EG003
Abdominal pain	Gastrointestinal disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0001 affected5 at risk EG0010 affected5 at risk EG0020 affected5 at risk EG003
Dental caries	Gastrointestinal disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0002 affected5 at risk EG0010 affected5 at risk EG0020 affected5 at risk EG003
Nausea	Gastrointestinal disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0001 affected5 at risk EG0011 affected5 at risk EG0020 affected5 at risk EG003
Headache	Nervous system disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0000 affected5 at risk EG0011 affected5 at risk EG0023 affected5 at risk EG003
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0001 affected5 at risk EG0010 affected5 at risk EG0021 affected5 at risk EG003
Fatigue	General disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage I	EG0001 affected5 at risk EG0012 affected5 at risk EG0020 affected5 at risk EG003
Pyrexia	General disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Nasopharyngitis	Infections and infestations	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0003 affected3 at risk EG0011 affected1 at risk EG0022 affected4 at risk EG003
Upper respiratory tract infection	Infections and infestations	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0001 affected3 at risk EG0010 affected1 at risk EG0021 affected4 at risk EG003
Gastroenteritis	Infections and infestations	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0021 affected4 at risk EG003
Influenza	Infections and infestations	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0011 affected1 at risk EG0020 affected4 at risk EG003
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0011 affected1 at risk EG0020 affected4 at risk EG003
Diarrhoea	Gastrointestinal disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0001 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Gastritis	Gastrointestinal disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0001 affected3 at risk EG0010 affected1 at risk EG0021 affected4 at risk EG003
Nausea	Gastrointestinal disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0021 affected4 at risk EG003
Headache	Nervous system disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0001 affected3 at risk EG0010 affected1 at risk EG0021 affected4 at risk EG003
Dizziness	Nervous system disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0001 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Hypoaesthesia	Nervous system disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0001 affected3 at risk EG0010 affected1 at risk EG0021 affected4 at risk EG003
Haemorrhage subcutaneous	Skin and subcutaneous tissue disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003
Iron deficiency anaemia	Blood and lymphatic system disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0001 affected3 at risk EG0011 affected1 at risk EG0020 affected4 at risk EG003
Anaemia	Blood and lymphatic system disorders	MedDRA version 19.0	Non-systematic Assessment	Study Period: Stage II	EG0000 affected3 at risk EG0010 affected1 at risk EG0020 affected4 at risk EG003

ID	Term
D008180	Lupus Erythematosus, Systemic
D001327	Autoimmune Diseases
D007154	Immune System Diseases

ID	Term
C568334	sifalimumab

OG003239.16(239.16 to 239.16)

OG0042308.44(2308.44 to 2308.44)

OG0055235.41± 11.6(4646.86 to 5857.94)

EG0050 events0 affected5 at risk

EG0040 affected5 at risk

EG0051 affected5 at risk

EG0040 affected5 at risk

EG0051 affected5 at risk

EG0040 affected5 at risk

EG0050 affected5 at risk

EG0040 affected5 at risk

EG0051 affected5 at risk

EG0040 affected5 at risk

EG0050 affected5 at risk

EG0041 affected5 at risk

EG0051 affected4 at risk

EG0040 affected5 at risk

EG0051 affected4 at risk

EG0040 affected5 at risk

EG0051 affected4 at risk

EG0040 affected5 at risk

EG0051 affected4 at risk

EG0041 affected5 at risk

EG0050 affected4 at risk

EG0041 affected5 at risk

EG0050 affected4 at risk

EG0040 affected5 at risk

EG0051 affected4 at risk

EG0040 affected5 at risk

EG0051 affected4 at risk

EG0041 affected5 at risk

EG0050 affected4 at risk

EG0040 affected5 at risk

EG0051 affected4 at risk

EG0041 affected5 at risk

EG0050 affected4 at risk

EG0040 affected5 at risk

EG0051 affected4 at risk

EG0040 affected5 at risk

EG0050 affected4 at risk

EG0040 affected5 at risk

EG0050 affected4 at risk

EG0040 affected5 at risk

EG0050 affected4 at risk

EG0040 affected5 at risk

EG0050 affected4 at risk

EG0040 affected5 at risk

EG0050 affected4 at risk

EG0041 affected5 at risk

EG0050 affected4 at risk

EG0040 affected5 at risk

EG0051 affected4 at risk

EG0041 affected5 at risk

EG0050 affected4 at risk

EG0052 affected5 at risk

EG0041 affected5 at risk

EG0051 affected5 at risk

EG0041 affected5 at risk

EG0050 affected5 at risk

EG0040 affected5 at risk

EG0050 affected5 at risk

EG0041 affected5 at risk

EG0050 affected5 at risk

EG0040 affected5 at risk

EG0050 affected5 at risk

EG0040 affected5 at risk

EG0050 affected5 at risk

EG0041 affected5 at risk

EG0050 affected5 at risk

EG0040 affected5 at risk

EG0051 affected5 at risk

EG0040 affected5 at risk

EG0050 affected5 at risk

EG0041 affected5 at risk

EG0051 affected4 at risk

EG0044 affected5 at risk

EG0053 affected4 at risk

EG0040 affected5 at risk

EG0052 affected4 at risk

EG0042 affected5 at risk

EG0051 affected4 at risk

EG0041 affected5 at risk

EG0050 affected4 at risk

EG0041 affected5 at risk

EG0050 affected4 at risk

EG0041 affected5 at risk

EG0050 affected4 at risk

EG0040 affected5 at risk

EG0051 affected4 at risk

EG0041 affected5 at risk

EG0050 affected4 at risk

EG0041 affected5 at risk

EG0051 affected4 at risk

EG0040 affected5 at risk

EG0050 affected4 at risk

EG0041 affected5 at risk

EG0050 affected4 at risk

EG0040 affected5 at risk

EG0052 affected4 at risk

EG0042 affected5 at risk

EG0050 affected4 at risk

EG0042 affected5 at risk

EG0051 affected4 at risk

ID	Term
D003240	Connective Tissue Diseases
D017437	Skin and Connective Tissue Diseases